Perioperative Toripalimab in Stage III Non–Small Cell Lung Cancer

Дата публикации: 01-09-2026 00:00:00

Fang et al present a post hoc analysis of the Neotorch trial—a multicenter, double-blind, placebo-controlled phase 3 study evaluating perioperative toripalimab (anti-PD-1 monoclonal antibody) combined with platinum-based chemotherapy. Prior trials suggest that neoadjuvant chemoimmunotherapy improves resection rates and R0 margins compared with chemotherapy alone, but benefits have not been consistently without coincident increases in treatment-related adverse events and surgery cancellations. Additional concerns persist that immunotherapy may increase fibrosis and inflammation, exacerbating operative difficulty and morbidity.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer	0	6.4	01-09-2026
2	Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery	0	7.22	10-09-2026
3	Q&A: Combining diagnosis, staging, tumor localization and surgery into a minimally invasive procedure for lung cancer	0	6.9	02-09-2026
4	FLOT-Induced vs CROSS-Induced Pathological Complete Response	0	8.96	01-09-2026
5	FLOT vs CROSS in Esophageal Adenocarcinoma	0	6.05	01-09-2026
6	Augmented Reality Thoracic Surgery and the Patient Experience	0	9.4	01-09-2026
7	Recalibrating “Unresectable” in Pancreatic Cancer	0	12.62	01-09-2026
8	MAIBE for Patients With Locally Advanced Pancreatic Cancer	0	5.92	01-09-2026
9	Immunotherapy increases risk for major cardiovascular events	0	10.61	23-09-2026
10	Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer	0	7.48	23-09-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.35. Источник: archderm.jamanetwork.com.